Table 7.
Summary of the utilities of adverse events or complications.
| Study | EPS | Weight gain | Diabetes | Others | References |
|---|---|---|---|---|---|
| Einarson et al. (15) | NA | ||||
| Lachaine et al. (16) | −0.074 | −0.031 | −0.06/−0.05* | Hypertension: −0.02 CHD: −0.07/−0.06* stroke: −0.17/−0.18* | (45, 55) |
| Park et al. (17) | −0.256 | NA | −0.151 | Hyperprolactinemia: −0.089 CHD: −0.151 | (46) |
| Dilla et al. (18) | −0.054 | −0.003 | NA | Sexual disfunction: −0.066 | From SOHO data |
| Druais et al. (21) | −0.197 | −0.094 | −0.15 | (46) | |
| Lin et al. (22) | 0.72*** | 0.77*** | 0.77*** | myocardial infarction: 0.74*** stroke: 0.64*** poststroke: 0.70*** | (45, 56, 57) |
| Rajagopalan et al. (23) | 89%** | 96%** | −0.15 | NA | (45, 46, 50) |
| Einarson et al. (24) | NA | ||||
| Einarson et al. (25) | NA | ||||
| Barnes et al. (26) | NA | NA | NA | Adverse events-0.006 | AMICUS trial |
| Einarson et al. (27) | NA | NA | NA | NA | NA |
| Einarson et al. (28) | NA | NA | NA | NA | NA |
| Wiwat et al. (29) | 0.62*** | 0.66*** | 0.66*** | Hyperprolactinemia: 0.62 | (22, 58) |
| Nuhoho et al. (30) | NA | ||||
| Aigbogun et al. (31) | −0.099 | −0.036 | NA | Akathisia: −0.09 pathoglycemia: −0.067 dyslipidemia: −0.099 sedation: −0.084 | (45, 59–61) |
| Németh et al. (32) | Not reported | Not reported | Not reported | Not reported | (62) |
| Zhao et al. (33) | 88.8%** | 95.9%** | NA | NA | (45) |
| Abdall-Razak et al. (34) | 88.8%** | 95.9%** | 0.76*** | Amputation: −0.109, non-fatal myocardial infarction: −0.129, non-fatal stroke: −0.181, heart failure: −0.108, ischemic heart disease: −0.132 | (45, 50, 56, 63) |
| Dutina et al. (35) | −0.256 | NA | NA | Metabolic syndrome: −0.132 | (46) |
| Arteaga et al. (36) | −0.256 | −0.089 | −0.151 | Prolactin-related syndrome: −0.089 | (46) |
| Yi et al. (37) | 0.72*** | 0.83*** | NA | increased blood glucose level: 0.77***, liver function damage 0.75***, hyperprolactinemia: 0.82*** | (45, 64) |
| Lin et al. (38) | 88.8%** | 95.9%** | 88.8%** | hyperlipidemia/hyperprolactinemia: 88.8%** | (45) |
| Jin et al. (39) | −0.07 | −0.03 | −0.09 | NA | (45, 56) |
*
Data presented as utility for male/utility for female.
**
Data presented as percentage reduction in utility for the presence of adverse effects.
***
Data presented as utility values.